Sanofi is rationing two Pompe disease medications, causing treatment delays or dosage reductions for patients. The shortage stems from manufacturing issues at the company’s production facility in Ireland.
The U.S. Food and Drug Administration (FDA) recently issued a warning regarding the Irish plant's operations. This regulatory scrutiny highlights potential lapses in Sanofi's quality control and production oversight.
The supply disruption threatens patient care and may impact Sanofi's revenue from these specific rare-disease treatments. Market analysts have not yet released specific data regarding the financial impact of this development.